UK markets closed
  • NIKKEI 225

    26,215.79
    +278.58 (+1.07%)
     
  • HANG SENG

    17,079.51
    -143.32 (-0.83%)
     
  • CRUDE OIL

    83.40
    +3.91 (+4.92%)
     
  • GOLD FUTURES

    1,704.20
    +32.20 (+1.93%)
     
  • DOW

    29,488.07
    +762.56 (+2.65%)
     
  • BTC-GBP

    17,354.32
    +241.69 (+1.41%)
     
  • CMC Crypto 200

    445.04
    +9.69 (+2.23%)
     
  • ^IXIC

    10,804.42
    +228.80 (+2.16%)
     
  • ^FTAS

    3,773.80
    +10.32 (+0.27%)
     

Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

·5-min read

DGAP-News: Gerresheimer AG / Key word(s): Alliance
Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
07.09.2022 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

  • Two leading companies joined forces to develop a new Ready-To-Use solution platform based on EZ-fill® pre-sterilized platform

  • Seamless integration into standard fill & finish lines

  • Significant increase in quality and efficiency

Düsseldorf, Germany / Piombino Dese, Italy – September 7, 2022 – Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics and Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology. This collaboration is projected to help customers gain efficiencies, improve the quality standard, increase speed to market, reduce total cost of ownership (TCO) and help mitigate supply chain risk.

Gerresheimer AG and Stevanato Group are addressing rising demand for RTU vials in the market and the partnership serves as a market enabler to fully support customers’ evolving needs and establish a gold standard in the industrial filling process. The collaboration aims to make RTU vials a standard, available to a wide number of pharma companies globally – offering premium quality solutions to patients and reducing complexity for pharma operations. The new solution will be available to other players in the market to standardize fill-finish operations from early phase drug development to commercialization. The new RTU solution platform from Gerresheimer AG and Stevanato Group will share the same secondary packaging, production process and sterilization method, ensuring consistent available capacity and a reliable double sourcing to the pharmaceutical industry. A hallmark of the new RTU platform is a significant reduction in particles, improving the overall quality and performance of the RTU solutions. In addition, customers can count on a high-end solution made by two major players in the drug containment industry with a long history of innovation. The new jointly developed vial platform and trademark will be presented in detail to the market at the CPhI Worldwide Frankfurt in November 2022.

“The new developed RTU platform stands out in terms of quality, TCO and sustainability and takes the use of RTU solutions like vials and, in the future, cartridges to a new level", said Dr. Lukas Burkhardt, Member of the Management Board of Gerresheimer AG. "Due to the strong reduction of the particle load, the quality is significantly increased. Our new innovative solution will convince the market to significantly accelerate the conversion from bulk to RTU Vials.”

“Our EZ-fill® vial platform is the market’s most established choice for pre-sterilized containers, and this enhanced version for RTU vials will bring to the market its full potential in terms of quality, flexibility and value for Pharmaceutical Companies and CMOs”, said Mauro Stocchi, Chief Business Officer at Stevanato Group. “Through our collaboration with Gerresheimer AG we are responding to market demand, and we expect to achieve another important milestone in creating a reliable ecosystem to support, accelerate and de-risk the conversion from bulk to EZ-fill® vials already underway in the market.”

For more information, visit www.gerresheimer.com or www.stevanatogroup.com


Contact Press Gerresheimer AG

Ueli Utzinger
Group Senior Director Marketing & Communication
T +49 211 6181-250
ueli.utzinger@gerresheimer.com

Contact Investor Relations Gerresheimer AG
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

 

Media contact Stevanato Group

Cassie Gonzalez
stevanatoUS@teamlewis.com

 

Investor Relations Stevanato Group

Lisa Miles
lisa.miles@stevanatogroup.com


About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

For more information: www.gerresheimer.com

 

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life science industries. The Group offers an integrated and comprehensive portfolio of products, processes and services that address customers' needs across the entire drug lifecycle at every stage of development, clinical and commercial. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are essential to its ability to offer value-added solutions to customers.

For more information: www.stevanatogroup.com

 


07.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Gerresheimer AG

Klaus-Bungert-Str. 4

40468 Düsseldorf

Germany

Phone:

+49-(0)211/61 81-314

Fax:

+49-(0)211/61 81-121

E-mail:

carolin.nadilo@gerresheimer.com

Internet:

http://www.gerresheimer.com

ISIN:

DE000A0LD6E6

WKN:

A0LD6E

Indices:

MDAX (Aktie)

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1436851


 

End of News

DGAP News Service

show this
show this